Abstract
CD103 is a transmembrane heterodimer complex that mediates cell adhesion, migration, and lymphocyte homing of cell through interaction with E-cadherin. Recently, CD103+ immune cells in human carcinoma has been investigated as a prognostic factor, however, the correlation between CD103+ immune cells and survival are still elusive. Therefore, a meta-analysis was performed to determine the prognostic value of CD103+ immune cells in solid tumor. Studies relevant to the subject was searched from PubMed, Embase, and Web of Science. Ten studies including 2,824 patients were eligible for the analysis. Tumors positive for CD103+ immune cells were associated with favorable overall survival, disease-free survival, and disease-specific survival. Subgroup analysis revealed that assessing CD103+ immune cells in epithelial and total (both epithelial and stromal) areas or using whole slide section were associated with good prognosis. Furthermore, stromal CD103+ immune cells or CD103+ immune cells evaluated by tissue microarrays were not always significantly prognostic. In conclusion, these results show that CD103+ immune cells are associated with prognosis in solid tumor. However, the region of assessment and selection of material for the evaluation could affect the value of CD103 as a prognostic biomarker.
Highlights
CD103, known as integrin αEβ7 (ITGAE), is a transmembrane heterodimer complex that is involved in cell to cell or cell to matrix interaction[1]
Intraepithelial CD8+ tumor-infiltrating lymphocytes (TILs) that expressed CD103 were suspected to cause exhausted phenotype by chronic stimulation that leads to resistance in immune therapy, and CD103 was widely co-expressed with PD-110
Expression of CD103 has been suggested as a marker of prolonged survival in solid tumors as well as a predictive marker of immunotherapy in recent years
Summary
CD103, known as integrin αEβ7 (ITGAE), is a transmembrane heterodimer complex that is involved in cell to cell or cell to matrix interaction[1]. CD103+ immune cells were a predictive marker of immunotherapy in lung cancer and increased expression was observed following anti-PD-1 therapy in ovarian cancer and melanoma[12,13,14]. A number of studies suggests that CD103+ TIL in human malignancy is associated with prognosis[15,16,17,18] This characteristic of CD103+ immune cells in cancer are still elusive with the exception of a meta-analysis of ovarian cancer[19]. Some studies define CD103 as predictive markers of intraepithelial CD8+ T cells or Tregs[20,21], but other studies show that CD103+ immune cells are present within the stroma[22] and could be considered to be associated with survival[23]. The aim of this study is to clarify the prognostic role of CD103 expression in immune cell as a biomarker across multiple tumors and to verify which region within tumor (epithelial, stromal, or both) and material (TMA or whole section) should be used in the assessment of the marker
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
